MPH Health Care AG publishes figures for the first half-year of 2025: Equity (NAV) amounts to EUR 205.1 million, which corresponds to EUR 47.91 per share. The equity ratio fell slightly to 93.7%

EQS-News: MPH Health Care AG

/ Key word(s): Half Year Results/Quarter Results

MPH Health Care AG publishes figures for the first half-year of 2025: Equity (NAV) amounts to EUR 205.1 million, which corresponds to EUR 47.91 per share. The equity ratio fell slightly to 93.7%

16.09.2025 / 08:30 CET/CEST

The issuer is solely responsible for the content of this announcement.

MPH Health Care AG publishes figures for the first half-year of 2025:

 Equity (net asset value) amounts to EUR 205.1 million, which corresponds to EUR 47.91 per share. The equity ratio fell slightly to 93.7% (31 December 2024: 95.5%)

Berlin, 16th September 2025 – MPH Health Care AG (ISIN: DE000A289V03) announces the preliminary IFRS consolidated results for the first half-year of 2025. Accordingly, equity decreased by 26% from EUR 277.9 million as of 31 December 2024 to EUR 205.1 million as of 30 June 2025. The net asset value (NAV) per share fell from EUR 64.90 (31 December 2024) to EUR 47.91 as of 30 June 2025.

The IFRS result for the period decreased from EUR 74.5 million as of 30 June 2024 to EUR -72.7 million as of 30 June 2025. This result is due to the accounting valuations of the investments as at the reporting date, which do not affect cash flow. MPH AG is an investment company whose investments are reported as financial assets under the balance sheet item ‘Financial investments’ and are measured at fair value through profit or loss on the balance sheet date.

The equity ratio fell slightly from 95.5% to 93.7% and remains at a very high level.

The financial position has improved compared to the previous year. From 1 January to 30 June 2025, an operating cash flow of kEUR 1,016 was generated (previous year: kEUR -895) and a net cash flow of kEUR 261 (previous year: kEUR -2,781).

The fair value losses are mainly due to the sharp decline in the share price of our listed investment CR Energy AG, which unexpectedly filed for (preliminary) insolvency proceedings with the competent local court in Potsdam in June 2025. The price of CR shares fell from EUR 4.78 on 31 December 2024 to EUR 0.54 on 30 June 2025.

The M1 Kliniken AG investment continued its growth trajectory in the first half of 2025, once again increasing both revenue and earnings. IFRS consolidated revenue in the first half of 2025 amounted to EUR 183.5 million, compared with EUR 167.7 million in the first half of 2024. This represents an increase of 9.4%. The Group EBIT margin increased by approximately 14% to 9.8% in the first half of 2025 (same period last year: 8.6%). Operating profit (EBIT) increased to EUR 18.0 million (previous year: EUR 14.5 million). Net profit (before minority interests) as of 30 June 2025 rose by around 19% to EUR 12.5 million.

M1 Kliniken AG continues to grow and aims to increase revenue in the high-margin beauty segment to EUR 200–300 million per year by 2029, with a sustainable EBIT margin of at least 20%. With a dividend payment of EUR 0.50 per share, M1 Kliniken AG is reaffirming its distribution policy.

At this year’s Annual General Meeting of MPH Health Care AG on 17 July 2025, it was resolved to distribute a dividend of EUR 1.20 per dividend-bearing share, as in the previous year, and to carry forward the remaining amount of the 2024 net profit of EUR 72.5 million to new account.

The half-yearly report of MPH Health Care AG is available for download under Financial Reports – MPH Health Care AG.

About MPH Health Care AG:

MPH Health Care AG is an investment company with a strategic focus on the acquisition, development and sale of companies and company shares, particularly in growth segments of the healthcare market. This includes both insurance-financed and privately financed segments. However, MPH also aims to exploit potential opportunities in high-growth and high-yield sectors outside the healthcare market.

 

Contact:
Patrick Brenske, Management Board
Corporate Communications
E-Mail: ir@mph-ag.de


16.09.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Gerresheimer delivers solid results in the financial year 2024 despite market headwinds

EQS-News: Gerresheimer AG

/ Key word(s): Annual Results

Gerresheimer delivers solid results in the financial year 2024 despite market headwinds

26.02.2025 / 07:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

Gerresheimer delivers solid results in the financial year 2024 despite market headwinds

  • Organic growth: revenue +2.9%, adjusted EBITDA +4.1%
  • Destocking in vial business partially offset by strong growth in medical devices
  • Growth strategy execution: capacity expansions and higher revenue share from solutions for biologics
  • Bormioli Pharma to boost revenues and adjusted EBITDA from 2025 with integration well underway

Duesseldorf, February 26, 2025: Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, achieved solid results and continued to grow profitably in financial year 2024. Revenues reached EUR 2,035.9m (2023: EUR 1,990.5m), while adjusted EBITDA amounted to EUR 419.4m (2023: EUR 404.5m). Organic sales grew by +2.9% and adjusted EBITDA by +4.1%. The adjusted EBITDA margin improved to 20.6% (2023: 20.3%). The Plastics & Devices Division benefited from the strong growth in medical devices, partially offsetting the destocking effects in the vial business in the Primary Packaging Glass Division. The first signs of a market recovery in the vial business were seen in the fourth quarter of 2024, but destocking effects at customers weighed on the results of the Primary Packaging Glass Division in the full year 2024. Bormioli Pharma will contribute significantly to the Group’s revenues and Adjusted EBITDA from the financial year 2025 while the integration into the Gerresheimer Group is well underway. For the financial year 2025, the combined group of companies including Bormioli Pharma now expects organic revenue growth of 3-5% compared to combined pro forma figures of the previous year. The adjusted EBITDA margin is expected to improve further to around 22%. The Group anticipates profitable growth in the coming years through the consistent execution of its growth strategy.

“2024 was characterized by temporary market effects in one of our submarkets,” says
Dietmar Siemssen, CEO of Gerresheimer AG. “Our long-term growth prospects remain positive. We are growing strongly in systems and solutions for large-molecule biologics for which we are systematically expanding our production capacities. With the acquisition of Bormioli Pharma, we have expanded our product portfolio and created the basis for new, integrated high value plastic solutions. All of this will help us to continue our profitable growth in the coming years.”

Plastics & Devices: Significant growth with improved margin
The Plastics & Devices Division generated revenue of EUR 1,141.3m in the financial year 2024 (2023: EUR 1,065.1m). Organic revenue growth amounted to 8.0%. The main driver of this positive development was the strong demand for drug delivery systems. Demand for plastic containment solutions also remained at a high level. Adjusted EBITDA reached EUR 293.7m (2023: EUR 270.0m). Adjusted EBITDA grew organically by 8.8% compared to the same period of the previous year. The division also increased its Adjusted EBITDA margin to 25.7% (2023: 25.3%). The positive development was driven by a higher proportion of specially tailored solutions for biologics, including GLP-1 products for the treatment of obesity.

Primary Packaging Glass: Destocking effects moderating
The first signs of a market recovery became visible in the fourth quarter of 2024, but business development in the Primary Packaging Glass Division in the financial year 2024 was still significantly influenced by destocking effects at pharmaceutical customers, particularly in the area of standard vials (“bulk vials”). Sales revenues reached EUR 898.6 million (2023: EUR 927.3 million). In organic terms, they were thus 2.6% below the same period of the previous year. Adjusted EBITDA amounted to EUR 177.2m (2023: EUR 182.5m). In organic terms, adjusted EBITDA was 2.4% below the prior-year period. The adjusted EBITDA margin remained stable at 19.7% (2023: 19.7%). Gerresheimer expects that destocking effects for standard vials will continue to moderate in the course of 2025.

High dividend continuity – dividend proposal of EUR 1.25
Gerresheimer’s adjusted net income increased to EUR 164.6m in the financial year 2024 (2023: EUR 158.0m). Adjusted EPS at constant currency rose to EUR 4.67 (2023: EUR 4.62). The Executive Board and Supervisory Board will therefore once again propose a dividend of EUR 1.25 per share for the financial year 2024 at the Annual General Meeting. This corresponds to a payout ratio of 26.0%. The proposed dividend is therefore within the payout range of 20% to 30%.

Bormioli Pharma – new category of high value plastic solutions through system integration

At the beginning of December 2024, Gerresheimer successfully completed the acquisition of the Bormioli Pharma Group. Bormioli Pharma will thus be fully consolidated in the Gerresheimer Group from the financial year 2025. The integration of the company is one of Gerresheimer’s focus topics of the financial year 2025 in order to seize the opportunities of the expanded product portfolio and the possibilities of system integration for new high-value plastic solutions. The acquisition also enables the formation of a stand-alone global moulded glass powerhouse.

Profitable growth expected in subsequent years

In view of the strong growth in systems and solutions for biologics, the successful execution of the growth projects in this area and the expanded portfolio of high value solutions, Gerresheimer expects profitable growth in the coming years.

Guidance for FY 2025 (organic)

  • Revenue growth: 3-5%
  • Adjusted EBITDA margin: around 22%
  • Adjusted EPS growth: high single-digit percentage range

Mid-term guidance (organic)

  • Revenue growth: 8-10 % CAGR
  • Adjusted EBITDA margin: 23 – 25%
  • Adjusted EPS growth: ≥ 10% CAGR

The Annual Report 2024 is available on the Gerresheimer website here:

https://www.gerresheimer.com/en/company/investor-relations/reports

 

About Gerresheimer
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets.  Together with Bormioli Pharma 2024, the Group generated revenues of around EUR 2.4bn and currently employs around 13,400 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
www.gerresheimer.com

Contact Gerresheimer AG

Media  
Jutta Lorberg
Head of Corporate Communication
T +49 211 6181 264

jutta.lorberg@gerresheimer.com
Marion Stolzenwald
Senior Manager Corporate Communication
T +49 172 2424185

marion.stolzenwald@gerresheimer.com
Investor Relations  
Guido Pickert
Vice President Investor Relations

T +49 152 900 14145
gerresheimer.ir@gerresheimer.com

 
Thomas Rosenke
Senior Manager Investor Relations
T: +49 211 6181-187
gerresheimer.ir@gerresheimer.com


26.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Straumann Group announces Executive Management Board changes

Straumann Holding AG

/ Key word(s): Personnel

Straumann Group announces Executive Management Board changes

26.02.2025 / 07:00 CET/CEST

Basel, February 26, 2025: Today the Straumann Group announces two executive management board changes. The first one is that Yang Xu, Chief Financial Officer(CFO), has decided to leave the Straumann Group as of May 2025 to pursue opportunities outside the company. The search for a new CFO has been started and succession will be announced shortly.

The second announcement is that Grant Bester will assume commercial responsibility for the North America region and join the Executive Management Board in April 2025. His onboarding will begin at the Straumann Group headquarters, alongside Guillaume Daniellot. In parallel, we would like to thank Aurelio Sahagun for his dedication and leadership over the past four years during which he guided the North America region through a challenging period. He will support a professional transition until the end of March, and then will pursue opportunities outside the company.

Guillaume Daniellot, Chief Executive Officer, said: “I would like to personally thank Yang Xu for her unwavering dedication in leading our finance organization. While I am sad to see her move on, I sincerely wish her all the best in her future endeavors. In addition, I’m very excited to soon have Grant on board. He is an exceptional, passionate leader with an impressive, strong, high-performance mindset and will further drive the success of our second-largest region, North America. I would also like to sincerely thank Aurelio for everything he has done for the company and wish him all the best for the future.“

Grant Bester to serve as Executive Commercial leader for North America 

As Executive Commercial Leader for North America, Grant Bester will assume commercial responsibility over the North America region and become a Member of the Executive Management Board. Grant joins from the Polaris Group where he was Vice President International for Polaris and then for Indian Motorcycle, overseeing the business internationally. Before that, Grant worked for Stryker, a global medical technology company, as Vice president and Chief Marketing officer. During his tenure, he was responsible for the orthopedics, trauma, and spinal business across multiple regions. Grant had a varied career, not only in corporate roles but has also been involved in entrepreneurial ventures, running his own business in professional imaging.

Born in 1971, Grant is South African-born, studied business management at the University of Johannesburg and furthered his executive education through programs at the Manchester Business School and Harvard University.

About Straumann Group

The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Medentika, Neodent, NUVO, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials and digital solutions for use in tooth correction, replacement and restoration or to prevent tooth loss. Headquartered in Basel, Switzerland, the Group currently employs close to 12’000 people worldwide. Its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland.
Phone: +41 (0)61 965 11 11
Homepage: www.straumann-group.com

Contacts:  

Corporate Communication

Silvia Dobry: +41 (0)61 965 15 62

Frank Keidel +41 (0)79 530 71 84

corporate.communication@straumann.com

Investor Relations

Marcel Kellerhals: +41 (0)61 965 17 51

Derya Güzel +41 (0)61 965 18 76

investor.relations@straumann.com

Disclaimer

This press release contains forward-looking statements, including statements regarding the beliefs, expectations and assumptions of future results, performance or achievements of Straumann Group, that are based upon information available to Straumann Group as of the date such statements are made. Forward-looking statements are neither historical facts nor assurances of future performance. They may, but need not, be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “believe,” “project,” “estimate,” “expect,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods or events. Such forward-looking statements reflect the views, beliefs, assumptions and expectations of Straumann Group or its management at the time the statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may be outside of Straumann Group’s control. Such known and unknown risks, uncertainties and other factors underlying forward-looking statements may cause the actual results, performance or achievements of the Group to differ materially from those expressed or implied in this document. Accordingly, you should not rely on any forward-looking statements contained in this press release. Important factors that could cause the Group’s expectations regarding future results, performance or achievements to differ materially from those expressed in a forward-looking statement include, but are not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann Group’s control. Should one or more of these risks, uncertainties or other factors materialize or should underlying views, beliefs, assumptions or expectations prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann Group is providing the information in this release as of the date it is issued and does not undertake any obligation to update any statements as a result of new information, future events or otherwise.This release constitutes neither an offer to sell nor a solicitation to buy any securities.

 


End of Media Release


show this

Affluent Medical appoints Liane Teplitsky – a senior executive in the medical device industry as a new member of the Board of Directors

EQS-News: Affluent Medical SA

/ Key word(s): Personnel

Affluent Medical appoints Liane Teplitsky – a senior executive in the medical device industry as a new member of the Board of Directors

25.02.2025 / 17:45 CET/CEST

The issuer is solely responsible for the content of this announcement.

 Affluent Medical appoints Liane Teplitsky – a senior executive in the medical device industry as a new member of the Board of Directors

Aix-en-Provence, February 25, 2025 – 5:45 p.m. CET – Affluent Medical (ISIN: FR0013333077 – Ticker: AFME – “Affluent”), a French clinical-stage medical technology company specializing in the international development and industrialization of innovative implantable medical devices, today announced it has coopted Liane Teplitsky as a new Board member.

Recently appointed CEO of Artedrone, the first autonomous robotic solution for Mechanical Thrombectomy, Liane Teplitsky is a successful seasoned senior executive in the medical device with achievements in building, leading, and growing innovative businesses that elevate the standard of patient care.

With an extensive background in R&D and a passion for advancing intelligent and life-changing medical technologies, Liane has cultivated an expertise in leading business strategy, clinical data development and commercialization for multimillion-dollar global medical technology franchises. Additionally, Liane has demonstrated excellence in building and leading highly functioning, highly engaged teams.

Most recently she was President, Global Robotics, Technology & Data Solutions at Zimmer Biomet where she led the global growth and development of the company’s portfolio of robotics and digital health technologies. Prior to Zimmer Biomet, Liane spent nearly a decade in executive leadership roles at Abbott as Vice President Sales & Division Vice President Marketing for Cardiac Arrhythmia & Heart Failure division and at St Jude Medical, with different strategic roles across multiple product and sales divisions.

Liane holds a Master of Science in Biomedical Engineering from Duke University and a Bachelor of Science in Electrical Engineering and a Bachelor of Science in Physiology from the University of Saskatchewan – Canada.

Sébastien Ladet, Affluent Medical CEO declares: “We are excited to welcome Liane to our board of Directors. Her extensive experience in both the healthcare and technology sectors, combined with her proven track record in leading market development and sales for medical devices, will be invaluable as we continue to advance in the clinical development of our 2 cutting-hedge medical devices to treat mitral valve regurgitation and prepare for their commercialisation.
 

About Affluent Medical

Affluent Medical is a French medical technologies company, founded by Truffle Capital, that aims to become a global leader in the treatment of structural heart diseases, one of the world’s leading causes of mortality, and urinary incontinence, which currently affects one in four adults.

Affluent Medical develops next-generation implants that are minimally invasive, innovative, adjustable and biomimetic, designed to restore essential physiological functions. The candidate products developed by the Company are all undergoing clinical studies in humans.

Subject to raising the funds necessary to finance its strategy and the positive results of ongoing clinical studies, the Company aims to gradually market its products from 2026, directly or indirectly.

For more information, please visit www.affluentmedical.com
 

Contacts:

AFFLUENT MEDICAL
 
Sébastien LADET
Chief Executive Officer
investor@affluentmedical.com
   SEITOSEI.ACTIFIN
   Financial communications / Press relations
   Ghislaine Gasparetto / Jennifer Jullia
   +33 (0)6 21 10 49 24 / +33 (0)1 56 88 11 19
   ghislaine.gasparetto@seitosei-actifin.com /
   jennifer.jullia@seitosei-actifin.com
PRIMATICE
Public Relations France
Thomas ROBOREL de CLIMENS
+33 (0)6 78 12 97 95
thomasdeclimens@primatice.com
   
   MC SERVICES AG

   Media relations Europe
   Maximilian SCHUR / Julia BITTNER
   +49 (0)211 529252 20 / +49 (0)211 529252 28
   affluent@mc-services.eu


25.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®

EQS-News: Formycon AG

/ Key word(s): Regulatory Approval

Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®

25.02.2025 / 06:30 CET/CEST

The issuer is solely responsible for the content of this announcement.

Press Release // February 25, 2025
 

Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®

  • FYB203 (aflibercept) approved in the UK for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases
  • UK market authorization follows successful regulatory approvals by the FDA and the European Commission for FYB203
  • Teva Pharmaceuticals will market FYB203 / AHZANTIVE® in major parts of Europe, including the United Kingdom

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its licensing partner Klinge Biopharma GmbH (Klinge) jointly announce that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved FYB203 (aflibercept), a biosimilar to Eylea®1, under the brand name AHZANTIVE®2. The approval covers the treatment of Age-Related Neovascular (wet) Macular Degeneration (nAMD) and other serious retinal conditions, including Diabetic Macular Edema (DME), visual impairment due to Myopic Choroidal Neovascularisation (CNV) and Macular Edema following Retinal Vein Occlusion (RVO).

“With the approval of FYB203, our second ophthalmic biosimilar in the UK, we take yet another significant step in making essential ophthalmic therapies more widely available,” said Dr. Stefan Glombitza, CEO of Formycon AG. “In addition to Ongavia®3, our successful ranibizumab biosimilar in the UK, AHZANTIVE® will provide a new, cost-efficient treatment option for patients with severe retinal diseases, through our strong commercial partner Teva.”

The U.S. Food and Drug Administration (FDA) had already granted marketing authorization for FYB203 in June 2024, followed by European Commission`s approval in January 2025.

Recently, Formycon and Teva Pharmaceuticals International GmbH (Teva) announced a partnership for the semi-exclusive commercialization of FYB203 across major parts of Europe, including the United Kingdom, and Israel. Concurrently, Formycon had concluded an agreement with Teva for product supply. Teva is already marketing Formycon’s FYB201 ranibizumab Biosimilar (Ongavia®) in the UK and can synergistically leverage an existing commercial infrastructure and well-established distribution channels in the ophthalmology field.

Aflibercept is an inhibitor of the vascular endothelial growth factor (VEGF), which plays a key role in the abnormal formation of blood vessels in the retina, leading to vision impairment.

—————

1) Eylea® is a registered trademark of Regeneron Pharmaceuticals Inc.
2) AHZANTIVE® is a registered trademark of Klinge Biopharma GmbH
3) Ongavia® is a registered trademark of Teva Pharmaceuticals Limited

 

About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/ranibizumab, Formycon already has a biosimilar on the market in Europe and the USA. Two further biosimilars, FYB202/ustekinumab and FYB203/aflibercept, have been approved by the FDA, EMA, and MHRA; FYB202 is also approved in Canada. Another four biosimilar candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines.

Formycon AG is headquartered in Munich, listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY and is part of the SDAX and TecDAX selection indices. Further information can be found at: https://www.formycon.com/

About Biosimilars:
Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare systems. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

About Teva:
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing its generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.

Contact:
Sabrina Müller,
Director Investor Relations & Corporate Communications,
Formycon AG
Fraunhoferstr. 15
82152 Planegg-Martinsried
Germany

Tel.: +49 (0) 89 – 86 46 67 149
Fax: + 49 (0) 89 – 86 46 67 110
Mail: Sabrina.Mueller@formycon.com

Disclaimer:
This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.


25.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Eckert & Ziegler Ensures Business Continuity After Cyber-Attack

EQS-News: Eckert & Ziegler SE

/ Key word(s): Miscellaneous

Eckert & Ziegler Ensures Business Continuity After Cyber-Attack

25.02.2025 / 09:59 CET/CEST

The issuer is solely responsible for the content of this announcement.

Berlin, 25 February 2025. Following a cyber-attack on the IT infrastructure of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) at the beginning of February, the Group’s business operations can continue in most areas. In a few cases, there are still restrictions due to the gradual restoration at one point or another. 

As of this week, all essential core systems are back in operation. In some cases, temporary solutions have been implemented to offer all business partners the full range of services again.

“We have temporarily converted some digital processes to manual processes in recent weeks. However, our production continues, and we can supply our customers,” explained Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. 

Eckert & Ziegler remains committed to upholding the highest standards of safety and integrity and thanks its patients, customers and partners for their patience and understanding during this incident.

“I would like to thank everyone involved for their tremendous efforts during the last few weeks. A special thanks goes to our colleagues in IT, who are giving their best to get us back up and running as quickly as possible. We kindly ask our business partners to continue to be understanding and patient if there are still temporary delays or restrictions in communication at the moment,” added Dr. Harald Hasselmann.

The Executive Board currently does not expect any significant adverse effects on the business.

Contact:
Eckert & Ziegler SE
Karolin Riehle
Investor Relations
Robert-Rössle-Str. 10
13125 Berlin
Tel. +49 30 94 10 84-138
Tel. +49 174 1785889
ir@ezag.com
www.ezag.com  


25.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

MeVis publishes figures for fiscal year 2023/2024 and forecast for 2024/2025

EQS-News: MeVis Medical Solutions AG

/ Key word(s): Annual Report/Annual Results

MeVis publishes figures for fiscal year 2023/2024 and forecast for 2024/2025

30.01.2025 / 12:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

  • Revenues of € 17.0 million
  • EBIT of € 3.5 million, 21% margin
  • Profit after tax € 4.6 million
  • Forecast for fiscal year 2024/2025
    • Slight increase in sales from € 17.0 million to € 17.5 million
    • EBIT between € 3.5 million and € 4.0 million

Bremen, January 30, 2025 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading medical imaging software company, announces its results for the fiscal year 2023/2024, with reporting period October 1, 2023 to September 30, 2024.

Revenues in the past fiscal year 2023/2024 amounted to €17.0 million (compared to €17.3 million in fiscal year 2022/2023). 25 % of sales revenues (previous year: 26%) are attributable to the sale of licenses, 35 % (previous year: 36 %) to maintenance revenues and 40 % (previous year: 38 %) to other revenues, which include, among other things, services for and recharges to affiliated companies and the parent company. The decline in license revenues compared to the previous year is mainly due to lower demand from our customers Philips and Canon. Maintenance revenues have fallen due to lower maintenance revenues from our customer Hologic. The year-on-year improvement in other revenues is due to a slight increase in diagnostic services and the reallocation of staff costs, rent and additional costs.

EBIT (earnings before interest and taxes) fell from € 3,895 k in the previous year to € 3,500 k in 2023/2024, mainly due to lower revenues, lower other operating income and higher staff costs. The EBIT margin fell accordingly from 23 % to 21 %.

Due to the tax group, only a small amount of income taxes of €0.1 million were incurred in the past financial year, the same as in the previous year.

This results in earnings after taxes of € 4.6 million (27 % margin) for fiscal year 2023/2024, compared to € 4.9 million (28 % margin) in 2022/2023. The profit of € 4,561 k will be transferred to Varex Imaging Deutschland AG under the domination and profit and loss transfer agreement .

For fiscal year 2024/2025, stable to slightly growing revenues in the range of € 17.0 million to € 17.5 million are expected. In addition to stable revenues from customer Hologic, slightly increasing revenues in the lung and liver segments are expected. In the area of development services, we expect a stable course. For earnings before interest and taxes (EBIT) for fiscal year 2024/2025 we expect a result between € 3.5 million and € 4.0 million, assuming a stable exchange rate of 1.12 USD/EUR. The forecast stability or slight increase in sales and the simultaneous disproportionately low increase in staff costs are the main drivers for the positive outlook for EBIT.

The half-year financial report for fiscal year 2024/2025 will be published on May 27, 2025.

 

Contact:
Kirchhoff, Marcus / CEO


30.01.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Takeda Pharmaceutical Company Limited: Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

Takeda Pharmaceutical Company Limited / Key word(s): Personnel

Takeda Pharmaceutical Company Limited: Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

30-Jan-2025 / 09:31 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


 

News Release

 

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

 

  • CEO Christophe Weber to retire from Takeda in June 2026 after 12 years
  • Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process

 

OSAKA, Japan and CAMBRIDGE, Massachusetts, January 30, 2025 – Takeda (TSE:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. Mrs. Kim will be proposed as a candidate for election to the Board at Takeda’s Annual General Shareholders Meeting held in June 2026. Mr. Weber will not hold a Board seat after retiring from Takeda.

 

“The Board of Directors has unanimously chosen Julie Kim to lead Takeda into the next chapter, building on the company’s success under Christophe Weber’s remarkable leadership,” said Masami Iijima, chair of the Board of Directors meeting and of the Nomination Committee. “During Christophe’s 12 years of leadership, Takeda has transformed into a competitive, global R&D-driven biopharmaceutical company, with a long-term sustainable business model. We are grateful for his tremendous impact and for his continued leadership at Takeda and support to Julie over the next 18 months. Julie is an outstanding leader who has made significant contributions to the company, notably in leading the U.S. business and the Plasma-Derived Therapies Business Unit previously. She is an experienced, values-based leader who will fully uphold our corporate culture and expand the impact we can have for patients around the world.”

 

Commenting on the selection process, Mr. Iijima said that “after undergoing a multi-year succession process, the Board determined that Julie Kim is the best leader among a strong pool of both internal and external candidates. The selection process followed by the Nomination Committee and the Board has been thorough and exemplary.”

 

“For several years, I have worked with the Board to ensure a smooth succession,” said Christophe Weber. “Now is the right time to appoint my successor given our competitive growth outlook, new product launches expected from the second half of 2026 onwards and the anticipated retirement of some external independent directors in the coming years. The Board’s selection of Julie is outstanding. I have worked closely with Julie for the past six years and have witnessed firsthand her values, intellect, grit and dedication to our people and patients.”

 

“Takeda is a unique company, and I am deeply honored to have been chosen to lead it,” said Julie Kim. “Thanks to Christophe’s phenomenal leadership, Takeda has become a global biopharmaceutical powerhouse with a promising late-stage pipeline. I am excited to guide Takeda through the next phase, together with our exceptional and talented people, while staying true to our strong culture that is rooted in our values and shaped by a heritage of more than 240 years. I want to thank the Board of Directors for their confidence in me. I look forward to working with the Board, Takeda’s executive team and all colleagues to serve and create long-term value for patients, shareholders and society.”

 

About Christophe Weber

Christophe Weber joined Takeda in April 2014 as chief operating officer. He was named president and representative director in June 2014, and subsequently appointed CEO in April 2015. Under Mr. Weber’s leadership, Takeda has focused on enhancing competitiveness through globalization and R&D transformation, while fostering a diverse and inclusive work environment and reinforcing ethical values and corporate governance.

 

About Julie Kim

Julie Kim has been the president of the U.S. Business Unit and U.S. country head since 2022, and a member of the Takeda Executive Team since 2019. With three decades of experience in health care, Mrs. Kim has held leadership positions at global, regional, country and functional levels. Her extensive background covers a range of therapeutic areas, international market access, general management, marketing and emerging market development.

 

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

 

Contacts:

 

Takeda Media Relations

Amy Atwood (U.S. & Global)

amy.atwood@takeda.com

 

Aya Shishido (Japan)

aya.shishido@takeda.com

 

Takeda Investor Relations

Christopher O’Reilly

Christopher.oreilly@takeda.com

+81 (0) 90-6481-3412

 

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

 

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 

Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

###

 

 

 

 

 

 

 

 

 

(Attachment)

 

 

  1. Changes in Appointment and Titles of Representative Directors
Name New Title (planned) Current Title
Julie Kim Representative Director, President & Chief Executive Officer* President, U.S. Business Unit and U.S. Country Head
Christophe Weber Retirement Representative Director, President & Chief Executive Officer

* Subject to election and appointment at the 150th Ordinary General Meeting of Shareholders and Board of Directors meeting in June 2026.

 

  1. Biography of Newly Appointed Representative Director
Date of Birth Business Experience Number of ADSs Held*
June 6, 1970 June 2016 Joined Shire plc
June 2016 Head of International Value Demonstration & Access
May 2018 Head of Global Hematology Franchise
January 2019 Joined Takeda Pharmaceutical Company Limited
January 2019 President, Plasma-Derived Therapies Business Unit
April 2022 President, U.S. Business Unit, and U.S. Country Head
 (to present)
95,065 ADSs

*There are no ordinary shares held as of the filing date.

 

  1. Effective Date of Changes (planned)

June 2026

 

 

 

 

End of Inside Information


30-Jan-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Lonza Delivers Solid 2024 Performance with CER Sales in Line with Prior Year and 29.0% CORE EBITDA Margin

Lonza Group AG / Key word(s): Annual Results

29-Jan-2025 / 06:25 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

  • In 2024, Lonza delivered sales of CHF 6.6 billion in line with prior year (-0.2% CER1)
  • CORE EBITDA of CHF 1.9 billion at a margin of 29.0%
  • The CDMO2  business delivered a strong commercial and operational performance, while Capsules & Health Ingredients (CHI) experienced market headwinds
  • The proposed dividend is maintained at CHF 4.00 per share
  • In 2025, Lonza expects CER sales growth approaching 20% and CORE EBITDA margin approaching 30% for the CDMO business
  • For its CHI business, Lonza expects sales and CORE EBITDA to return to growth in 2025, with low-to-mid-single-digit CER sales growth and a CORE EBITDA margin in the mid-twenties

Basel, Switzerland, 29 January 2025 – Lonza has reported sales of CHF 6.6 billion (-0.2% CER and -2.1% AER3 compared to the prior year). A CORE EBITDA of CHF 1.9 billion resulted in a robust margin of 29.0%, driven by high demand for commercial CDMO services and strong operational execution. Adjusted for the COVID-related mRNA business and the related termination impact in 2023, underlying sales grew at around 7% in CER and CORE EBITDA margin improved by low-single-digit ppts.

CDMO sales were driven by low-teens underlying CER growth, supported by strong performance in the Mammalian, Bioconjugates, Small Molecules and Cell & Gene Technologies businesses. This positive momentum compensated for the 2023 loss of COVID-related mRNA business, lower market demand for capsules within the CHI division, and softness in the Bioscience business.

 

Business highlights in 2024 included generally strong order momentum and contract signings worth around CHF 10 billion. Lonza also successfully closed the acquisition of the Genentech large-scale mammalian facility in Vacaville (US) from Roche on 1 October 2024 and has since then signed two new customer contracts. With CHF 1.4 billion of CapEx in 2024 (22% of sales), Lonza also made good progress in executing its ongoing organic investment program to enable future growth across technologies.

 

At its Investor Update in December 2024, Lonza announced its new vision and One Lonza strategy centered around the Lonza Engine, which brings together the company’s unique core competencies that enable outstanding value creation. As part of this, Lonza announced its intention to exit the CHI business and evolve into a pure-play CDMO. The separation will be effected at the appropriate time and in the best interests of shareholders and stakeholders, while ensuring CHI continues to serve its customers and deliver profitable growth as the global market leader in its space. In support of the One Lonza strategy and to prepare for future growth, a streamlined operating model will be implemented in Q2 2025 with three newly-formed Business Platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities. Furthermore, Lonza will expand the importance of bolt-on M&A and take an impartial approach to organic and inorganic growth opportunities going forward.

 

Lonza continued to make progress on its ESG commitments in 2024. Half of the company’s electricity now comes from renewable sources, supported by the commencement of photovoltaic production in Spain under a Virtual Power Purchase Agreement covering all Lonza sites across Switzerland and the European Union.

 

For 2025, Lonza expects strong performance in its CDMO business with CER sales growth approaching 20% and CORE EBITDA margin approaching 30%. Excluding Vacaville, which is expected to contribute around CHF 0.5 billion in sales at lower profitability, Lonza expects low-teens organic CER sales growth and margin improvement in its CDMO business.

 

For CHI, Lonza expects sales and CORE EBITDA to return to growth in 2025, with low-to-mid-single-digit CER sales growth and a CORE EBITDA margin in the mid-twenties.

 

Wolfgang Wienand, CEO, commented: “In 2024, our market-leading CDMO businesses demonstrated good commercial momentum with high contract signings across technologies. Looking ahead to 2025 and beyond, we are focusing on implementing our One Lonza strategy and a simplified, easy-to-scale organizational structure. This will facilitate future growth and create an even better experience for our customers across the different service offerings. Together as a global team, we have embarked on our journey to turn One Lonza into a reality.”

 

Lonza’s Board of Directors will propose to maintain a dividend of CHF 4.00 per share at the Lonza AGM in May 2025. Subject to approval, 50% of the dividend will be paid out of the capital contribution reserve, meaning it will be free from Swiss withholding tax.

 

Based on its strong balance sheet and positive outlook, Lonza continued to return excess capital to shareholders through the share buyback program of up to CHF 2 billion announced in March 2023. As of 31 December 2024, shares worth approximately CHF 1.7 billion were repurchased. The full buyback program is expected to be completed as planned in Q1 2025.

 

Divisional Overview

 

  • Biologics reported sales in line with prior year (-0.5%4), with growth from sustained commercial demand offset by the loss of COVID-related mRNA business and the related termination impact in 2023. The CORE EBITDA margin of 34.4% was supported by a favorable product mix and strong operational performance, partially offset by the ramp-up costs of new manufacturing assets. Excluding the COVID-related mRNA business in 2023, Biologics delivered low-teens underlying sales growth and CORE EBITDA margin expanded significantly compared to prior year.
  • Small Molecules reported sales growth of 9.3%4 compared to prior year at a strong CORE EBITDA margin of 35.7%, driven by high commercial demand, strong operational performance and the division’s continued portfolio shift to high-value products and complex service offerings.
  • Cell & Gene reported sales growth of 1.1%4 compared to prior year. This was driven by strong operational performance in Cell & Gene Technologies and partially offset by softer performance in Bioscience. Compared to 2023, the division significantly improved its CORE EBITDA margin by 5.9 ppts. This was supported by Cell & Gene Technologies achieving positive margins and productivity measures in Bioscience. Excluding the one-off contribution from the Codiak BioSciences termination in 2023, divisional sales grew at a robust 10%4.
  • Capsules & Health Ingredients reported a sales decline of 6.6%4 as a result of soft demand for pharma capsules due to customer destocking. In late 2024, the nutraceutical capsules business saw a return to pre-COVID volumes albeit still at a lower price level, while Dosage Form Solutions benefited from solid growth. The division reported a CORE EBITDA margin of 24.3%, impacted by lower asset utilization due to softer demand and lower nutraceutical prices. This was partially offset by productivity initiatives across the network, including the positive early impact of its newly-introduced superior proprietary D90 capsule manufacturing technology, and cost containment measures.

 

Group Financial Summary

CHF million

 

FYR 2024

 

YoY change (in %)

 

FYR 2023

Sales in AER

 

6,574

 

-2.1

 

6,717

CORE EBITDA

 

1,908

 

-4.6

 

1,999

    Margin in %

 

29.0

 

-0.8ppts

 

29.8

EBITDA

 

1,695

 

-12.6

 

1,940

    Margin in %

 

25.8

 

-3.1ppts

 

28.9

 

For more details, please refer to the Full-Year 2024 Presentation, Full-Year 2024 Report and Alternative Performance Measures (APM) 2024 Report.

 

1Constant Exchange Rates.
2CDMO: Lonza excluding Capsules & Health Ingredients (CHI).
3Actual Exchange Rates.
4Sales growth figures, expressed as a percentage (%) at Constant Exchange Rates (CER).

About Lonza
Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of approximately 18,500 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. We support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.

Our company generated sales of CHF 6.6 billion with a CORE EBITDA of CHF 1.9 billion in Full-Year 2024. Find out more at www.lonza.com

Follow @Lonza on LinkedIn
Follow @LonzaGroup on X

Lonza Contact Details

Victoria Morgan
Head of External Communications
Lonza Group Ltd

Tel +41 61 316 2283
victoria.morgan@lonza.com

Daniel Buchta
Head of Investor Relations
Lonza Group Ltd
Tel +41 61 316 2985

daniel.buchta@lonza.com


End of Inside Information


show this

Abivax Publishes 2025 Financial Calendar

EQS-News: ABIVAX

/ Key word(s): Miscellaneous

Abivax Publishes 2025 Financial Calendar

28.01.2025 / 08:30 CET/CEST

The issuer is solely responsible for the content of this announcement.

Abivax Publishes 2025 Financial Calendar

PARIS, France – January 28, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today published its expected 2025 financial communications calendar.

Monday, March 24, 2025 (after US Market closes)

2024 Annual Business and Financial Report (as of December 31, 2024)

  • Press Release
  • Universal Registration Document (Euronext)
  • Annual Report on Form 20-F

Monday, June 2, 2025 (after US Market closes)

2025 Q1 Financial Results (as of March 31, 2025)

  • Press Release
  • Report on Form 6-K

Friday, June 6, 2025

 2025 Annual General Meeting (AGM)

  • Live meeting in Paris, France

Monday, August 11, 2025 (after US Market closes)

2025 Half-Year Business and Financial Report (as of June 30, 2025)

  • Press Release
  • Half-Year Financial Report (Euronext)
  • Report on Form 6-K

Monday, December 15, 2025 (after US Market closes)

2025 Q3 Financial Results (as of September 30, 2025)

  • Press Release
  • Report on Form 6-K

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:

Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company’s business and financial objectives. Words such as “anticipate,” “expect,” “potential” and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning the Company’s expectations for publishing its financial results throughout 2025. Although Abivax’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d’Enregistrement Universel) and in its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on April 5, 2024 under the caption “Risk Factors.” These risks, contingencies and uncertainties include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, and the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development, including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell or the solicitation of an offer to purchase or subscribe for securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.


28.01.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this